Adapalene 0.2% | Clindamycin 2% | Niacinamide 4% | Tea Tree Oil

Applied topically once daily to the affected acne-prone areas of the face (or other affected regions) as a thin, even layer.

• Apply to clean, dry skin (wait 20–30 minutes after cleansing to minimize irritation).
• Avoid the eye area, lips, nasal mucosa, and any open wounds.
• Apply in the evening — adapalene increases photosensitivity; sun protection (SPF ≥30) is essential during daytime hours.
• Start with every-other-day application if significant dryness or irritation occurs; titrate to nightly as tolerated.

For topical acne preparations of this class:

• Apply a thin layer once daily (typically at bedtime) to affected areas.
• An initial adjustment period of 4–8 weeks is expected, during which mild irritation, peeling, and purging may occur.
• Clinical response is typically assessed at 8–12 weeks.
• Clindamycin monotherapy should not continue indefinitely; the prescriber should reassess antibiotic component necessity at each follow-up to minimize resistance development.
• Final dosing and duration are prescriber-determined.

• Adapalene: Binds RAR-β and RAR-γ nuclear receptors and, in complex with retinoid X receptors, modulates transcription of genes regulating follicular keratinocyte differentiation (normalizing desquamation and reducing comedone formation). Independently down-regulates TLR-2 expression and AP-1 transcription factor activity, reducing C. acnes–driven inflammatory signaling.
• Clindamycin: Binds the 23S rRNA of the 50S ribosomal subunit, blocking transpeptidation and peptide chain elongation in C. acnes, reducing bacterial burden and associated inflammation (lipase-mediated free fatty acid production, chemotactic factor release).
• Niacinamide: Inhibits the transfer of melanosomes from melanocytes to surrounding keratinocytes (reducing post-inflammatory hyperpigmentation); upregulates ceramide synthesis to reinforce the stratum corneum barrier; inhibits PARP-1 and suppresses inflammatory cytokine release; reduces sebum excretion rates.
• Tea Tree Oil (terpinen-4-ol): Disrupts C. acnes cell membrane integrity; inhibits pro-inflammatory cytokines (IL-1β, TNF-α) in activated monocytes; provides additional antimicrobial activity against antibiotic-resistant strains.

This multi-modal acne preparation addresses all four pathophysiologic pillars of acne vulgaris:

• Follicular hyperkeratinization — adapalene normalizes keratinocyte differentiation, preventing comedone formation.
• C. acnes colonization — clindamycin and tea tree oil provide complementary antimicrobial coverage.
• Inflammation — adapalene (TLR-2/AP-1), niacinamide (cytokine modulation), and tea tree oil each contribute anti-inflammatory effects.
• Post-inflammatory hyperpigmentation (PIH) — niacinamide reduces melanosome transfer, addressing a common sequela of inflammatory acne particularly in darker skin phototypes.

Monitoring:

• Assess for antibiotic resistance by minimizing clindamycin monotherapy duration; limit use to 12 weeks when possible or pair with a non-antibiotic antimicrobial (e.g., benzoyl peroxide) to reduce resistance risk.
• Evaluate response at 8–12 weeks; reassess irritation and sun protection compliance at each visit.

Contraindications:

• Hypersensitivity to adapalene, clindamycin, lincomycin, niacinamide, or tea tree oil.
• History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (clindamycin).

Warnings & Precautions:

• Adapalene is teratogenic in animal studies at supratherapeutic systemic doses; avoid in pregnancy (topical systemic absorption is very low, but prescriber should assess risk-benefit).
• Photosensitivity: adapalene significantly increases UV sensitivity — strict daily SPF ≥30 use is required.
• Irritant dermatitis (dryness, peeling, erythema) is common during the first 4–8 weeks of retinoid use; typically self-limiting.
• Clindamycin: very rare risk of C. difficile–associated diarrhea from topical use; instruct patients to report diarrhea.

Drug Interactions:

• Avoid concomitant use of other potentially irritating topical agents (benzoyl peroxide on same area at same time, salicylic acid peels) without prescriber guidance.
• Clindamycin may antagonize the antibacterial action of erythromycin (if combined topically).

Common Side Effects: Erythema, dryness, peeling, and stinging at the application site (particularly with adapalene); mild photosensitivity; rare contact allergy to tea tree oil.

Store at room temperature (15–25°C), in a cool, dry location away from direct light. Keep tightly sealed. Do not freeze. Keep out of reach of children. Use by the beyond-use date assigned by Genesis Compounding per USP <795>.

Why does my skin get red and peel when I start this cream?

Initial dryness, redness, and peeling are expected during the first 4–8 weeks of adapalene use (a retinoid). This represents the medication working to normalize skin cell turnover. Start every other day if irritation is significant, and gradually increase to nightly use as tolerated.

Why is an antibiotic included in this topical preparation?

Clindamycin 2% targets Cutibacterium acnes, the bacterium that colonizes acne lesions and drives inflammation. Combining an antibiotic with a retinoid and other anti-inflammatory agents is standard multimodal acne management per AAD guidelines.

What does niacinamide do for my skin?

Niacinamide reduces the transfer of pigment-containing melanosomes into skin cells, helping prevent and fade post-inflammatory dark spots (hyperpigmentation) after acne lesions resolve. It also strengthens the skin barrier and reduces redness.

Is this preparation FDA-approved?

No. This is a patient-specific, 503A compounded preparation from Genesis Compounding. While some individual components are available in FDA-approved products, this specific multi-ingredient combination is compounded to order.

Do I need sunscreen while using this?

Yes — daily use of SPF ≥30 broad-spectrum sunscreen is required. Adapalene (a retinoid) significantly increases the skin's sensitivity to UV radiation, and UV exposure can both worsen acne and trigger post-inflammatory pigmentation.